meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
ipilimumab plus gp100
ipilimumab plus SoC
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (2mg/kg)
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs Immunostimulant
vs vaccine
vs gp100
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Ipilimumab (10 mg/kg)
title
ipilimumab alone
title
gp100
title
CA184-004, 2011 NCT00261365 mML - L2 - all population 40/42
Ascierto (ipi 10 vs 3 mg/kg), 2017 NCT01515189 mML - L2 - all population 365/362
MDX010 Ipi vs gp100, 2010 NCT00094653 mML - L2 - all population 137/136
Pathology:
mML - L2 - all population;
mML - L2 - all population
CA184-004, 2011
Ascierto (ipi 10 vs 3 mg/kg), 2017
MDX010 Ipi vs gp100, 2010
Ipilimumab (10 mg/kg)
2
T1
T1
ipilimumab alone
1
T0
T0
T1
gp100
0
T0